missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human UGCG (aa 34-140) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (99%), Rat (99%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-54986 (PA5-54986. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
May serve as a 'flippase' as well as a glucosyltransferase that transfers glucose to ceramide. It Catalyzes; UDP-glucose + Nacylsphingosine = UDP + D-glucosyl-N-acylsphingosine. Ceramide Glycosyltransferase is the first step in the Glycosphingolipid synthesis; first glycosylation step. Glucosylceramide synthase (GlcT) and lactosylceramide synthase (GalT) are key enzymes for the synthesis of major glycosphingolipids of vertebrates.
Specifications
Specifications
| Accession Number | Q16739 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 7357 |
| Name | Human UGCG (aa 34-140) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | AU043821; C80537; cb539; Ceramide glucosyltransferase; ectoplacental cone, invasive trophoblast giant cells, extraembryonic ectoderm and chorion sequence 21; Epcs21; GCS; GlcT; GLCT1; GLCT-1; glucosylceramide synthase; hypothetical protein LOC553944; sb:cb539; UDP-glucose ceramide glucosyltransferase; UDP-glucose:ceramide glycosyltransferase; UDP-glucose:N-acylsphingosine D-glucosyltransferase; Ugcg; Ugcgl; zgc:112506 |
| Common Name | UGCG |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction